Evotec and Indivumed join forces in CRCEvotec SE and Indivumed GmbH have entered into a drug R&D collaboration aimed at developing first-in-class colorectal cancer treatments. more ➔
Theranexus colloborates with AI expert DylissLyon-based neurology specialist Theranexus SA has launched a new bioinformatics partnership with systems biology data analysts from Dyliss (Dynamics, Logics and Inference for biological Systems and … more ➔
uniQure Receives FDA Fast Track Designation for AMT-130Following the FDA granted AMT-130 fast track designation, uniQure NV announced it will start Phase I/II testing of the Huntington’s Disease gene therapy in Q2/2019. more ➔
Sanofi ends option phase of rare disease partnership with AlnylamSanofi and Alnylam have agreed to end the research and option phase of the companies’ RNAi therapeutics alliance in rare genetic diseases. more ➔
Medigene AG in potential €1bn licence and R&D dealRoivant Sciences and Sinovant Sciences have launched newco Cytovant Sciences, which licenced two T cell-based cancer immune therapies and two development programmes from Medigene AG for commercialisation … more ➔
AMR diagnostic specialist Gradientech raise $4.6mGradientech closes a USD 4.6 million rights issue to progress QuickMIC diagnostic system for ultra-rapid antibiotics susceptibility testing (AST). more ➔
123rf.com/Iculig AgomAb Therapeutics bags €21m Series A financingAgomAb Therapeutics, a company resulting from a collaboration of argenx SE and growth factor experts from the University of Turin, has completed a €21m Series A financing. more ➔
Novartis acquires inflammasome blocker company IFM TreNovartis has aquired all outstanding capital stock and paid US$310m upfront to Boston-based IFM Tre Inc., which commercialises three inflammasome blockers designed to treat chronic inflammatory dise … more ➔
EMA recommends bluebird’s ?-thalassemia gene therapyThe European Medicines Agency has granted conditional approval for bluebird bio NV’s gene therapy Zynteglo (LentiGlobin BB305) to treat the rare disease transfusion-dependent ?-thalassemia at its … more ➔
Selvita to spin out cancer businessKrakow-based Selvita S.A. has announced it will spin out its oncology unit this year resulting in two public companies, a CRO and a cancer therapeutics developer. more ➔
123rf.com/Iculig
